These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 33397269)

  • 1. Synergistic Interactions between GW8510 and Gemcitabine in an In Vitro Model of Pancreatic Cancer.
    Rüstem DG; Atay S; Aydin HH; Ak H
    Anticancer Agents Med Chem; 2021 Oct; 21(16):2204-2215. PubMed ID: 33397269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine resistance mediated by ribonucleotide reductase M2 in lung squamous cell carcinoma is reversed by GW8510 through autophagy induction.
    Chen P; Wu JN; Shu Y; Jiang HG; Zhao XH; Qian H; Chen K; Lan T; Chen CG; Li J
    Clin Sci (Lond); 2018 Jul; 132(13):1417-1433. PubMed ID: 29853661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2).
    Xia G; Wang H; Song Z; Meng Q; Huang X; Huang X
    J Exp Clin Cancer Res; 2017 Aug; 36(1):107. PubMed ID: 28797284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential processing of let-7a precursors influences RRM2 expression and chemosensitivity in pancreatic cancer: role of LIN-28 and SET oncoprotein.
    Bhutia YD; Hung SW; Krentz M; Patel D; Lovin D; Manoharan R; Thomson JM; Govindarajan R
    PLoS One; 2013; 8(1):e53436. PubMed ID: 23335963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ribonucleotide reductase M2 does not predict survival in patients with resectable pancreatic adenocarcinoma.
    Xie H; Lin J; Thomas DG; Jiang W; Liu X
    Int J Clin Exp Pathol; 2012; 5(4):347-55. PubMed ID: 22670179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1).
    Vena F; Li Causi E; Rodriguez-Justo M; Goodstal S; Hagemann T; Hartley JA; Hochhauser D
    Clin Cancer Res; 2015 Dec; 21(24):5563-77. PubMed ID: 26228206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the Warburg effect with a novel glucose transporter inhibitor to overcome gemcitabine resistance in pancreatic cancer cells.
    Lai IL; Chou CC; Lai PT; Fang CS; Shirley LA; Yan R; Mo X; Bloomston M; Kulp SK; Bekaii-Saab T; Chen CS
    Carcinogenesis; 2014 Oct; 35(10):2203-13. PubMed ID: 24879635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquired tamoxifen resistance is surmounted by GW8510 through ribonucleotide reductase M2 downregulation-mediated autophagy induction.
    Li ZN; Shu Y; Chen CG; Li XQ; Li MY; Zhao XH; Wang S; Li J
    Biochem Biophys Res Commun; 2020 Jul; 528(3):554-560. PubMed ID: 32505349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MiR-20a-5p regulates gemcitabine chemosensitivity by targeting RRM2 in pancreatic cancer cells and serves as a predictor for gemcitabine-based chemotherapy.
    Lu H; Lu S; Yang D; Zhang L; Ye J; Li M; Hu W
    Biosci Rep; 2019 May; 39(5):. PubMed ID: 30777929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vasohibin 2 reduces chemosensitivity to gemcitabine in pancreatic cancer cells via Jun proto-oncogene dependent transactivation of ribonucleotide reductase regulatory subunit M2.
    Tu M; Li H; Lv N; Xi C; Lu Z; Wei J; Chen J; Guo F; Jiang K; Song G; Gao W; Miao Y
    Mol Cancer; 2017 Mar; 16(1):66. PubMed ID: 28327155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-211 modulates gemcitabine activity through downregulation of ribonucleotide reductase and inhibits the invasive behavior of pancreatic cancer cells.
    Maftouh M; Avan A; Funel N; Frampton AE; Fiuji H; Pelliccioni S; Castellano L; Galla V; Peters GJ; Giovannetti E
    Nucleosides Nucleotides Nucleic Acids; 2014; 33(4-6):384-93. PubMed ID: 24940696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine.
    Duxbury MS; Ito H; Zinner MJ; Ashley SW; Whang EE
    Oncogene; 2004 Feb; 23(8):1539-48. PubMed ID: 14661056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.
    Fujita H; Ohuchida K; Mizumoto K; Itaba S; Ito T; Nakata K; Yu J; Kayashima T; Souzaki R; Tajiri T; Manabe T; Ohtsuka T; Tanaka M
    Neoplasia; 2010 Oct; 12(10):807-17. PubMed ID: 20927319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells.
    Duxbury MS; Ito H; Zinner MJ; Ashley SW; Whang EE
    Clin Cancer Res; 2004 Apr; 10(7):2307-18. PubMed ID: 15073106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer.
    Massihnia D; Avan A; Funel N; Maftouh M; van Krieken A; Granchi C; Raktoe R; Boggi U; Aicher B; Minutolo F; Russo A; Leon LG; Peters GJ; Giovannetti E
    J Hematol Oncol; 2017 Jan; 10(1):9. PubMed ID: 28061880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pegylated arginine deiminase synergistically increases the cytotoxicity of gemcitabine in human pancreatic cancer.
    Daylami R; Muilenburg DJ; Virudachalam S; Bold RJ
    J Exp Clin Cancer Res; 2014 Dec; 33(1):102. PubMed ID: 25499121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.
    Bianco C; Giovannetti E; Ciardiello F; Mey V; Nannizzi S; Tortora G; Troiani T; Pasqualetti F; Eckhardt G; de Liguoro M; Ricciardi S; Del Tacca M; Raben D; Cionini L; Danesi R
    Clin Cancer Res; 2006 Dec; 12(23):7099-107. PubMed ID: 17145834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ARID1A promotes chemosensitivity to gemcitabine in pancreatic cancer through epigenetic silencing of RRM2.
    Li W; Chen Q; Gao W; Zeng H
    Pharmazie; 2022 Sep; 77(7):224-229. PubMed ID: 36199183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of 12-O-tetradecanoylphorbol-13-acetate in combination with gemcitabine on Panc-1 pancreatic cancer cells cultured in vitro or Panc-1 tumors grown in immunodeficient mice.
    Zheng X; Cui XX; Gao Z; Verano M; Huang MT; Liu Y; Rabson AB; Conney AH
    Int J Oncol; 2012 Dec; 41(6):2269-75. PubMed ID: 23041978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. E2F2 enhances the chemoresistance of pancreatic cancer to gemcitabine by regulating the cell cycle and upregulating the expression of RRM2.
    Liu Q; Song C; Li J; Liu M; Fu L; Jiang J; Zeng Z; Zhu H
    Med Oncol; 2022 Jun; 39(9):124. PubMed ID: 35716217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.